However, few BACE1 inhibitors have been marketed to treat AD due to the difficulty in developing therapeutic agents that can efficiently cross the BBB and reach appropriate concentrations in the cerebral parenchyma, and, moreover, can do so without side effects [34]. Here, BACE1 is linked to Alzheimer disease.